Using PET imaging to measure brain changes in Alzheimer's disease
PET imaging for in-vivo quantification of demyelination and cerebral perfusion in Alzheimer's Disease
This study is looking at a new type of brain scan to better understand changes in the brains of people with Alzheimer's disease, using a special tracer that helps show areas where the brain's protective covering is damaged, and it’s for patients who want to help improve how we track these changes over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11193460 on NIH RePORTER |
What this research studies
This research investigates the use of a new PET imaging technique to quantify demyelination and cerebral blood flow in patients with Alzheimer's disease. By utilizing a radiotracer called [18F]3F4AP, which binds to specific channels that become exposed during demyelination, the study aims to provide more accurate measurements of brain changes associated with Alzheimer's. This approach seeks to overcome the limitations of traditional imaging methods, offering insights into both white and gray matter changes in the brain. Patients participating in this research may undergo PET scans to help assess the extent of these changes over time.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or related dementias who are experiencing cognitive decline.
Not a fit: Patients with other forms of dementia not related to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and treatment strategies for Alzheimer's disease by providing a clearer understanding of brain pathology.
How similar studies have performed: Previous studies have shown success in using PET imaging for other neurological conditions, suggesting potential for this novel approach in Alzheimer's disease.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Guehl, Nicolas Jean — Yale University
- Study coordinator: Guehl, Nicolas Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.